PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2022
CASE
AUTH/3690/8/22 GlaxoSmithKline

GSK: Senior medical employee β€˜loved’ LinkedIn post seen as disseminating off-label promotion for Jemperli (AUTH/3690/8/22)

A senior UK-based GSK medical employee β€˜loved’ an external LinkedIn post about rectal cancer immunotherapy. Panel said this likely disseminated off-label promotion…

2023
CASE
AUTH/3762/4/23 SyriMed

AUTH/3762/4/23: Complainant v SyriMed (Thame Laboratories) β€” representative exam allegation (No breach)

Ex-employee alleged an individual promoted medicines to HCPs for 2+ years without ABPI qualification. Panel found no evidence for the 2-year claim…

2023
CASE
AUTH/3746/2/23 Moderna

Moderna: ECCMID β€œproduct theatre” presentation ruled promotional and inconsistent with Spikevax SPC (AUTH/3746/2/23)

At ECCMID 2022, a UK HCP presentation was ruled promotional for Spikevax and included booster-dose data inconsistent with the SPC. Breaches: Clauses…

2023
CASE
AUTH/3801/7/23 AstraZeneca

AUTH/3801/7/23: Complainant v AstraZeneca β€” LinkedIn β€˜About’ section alleged public promotion (No breach)

Complaint alleged a senior AstraZeneca leader’s LinkedIn β€˜About’ section promoted POMs to the public and referenced unlicensed indications/trials. Panel ruled no breach…

2023
CASE
AUTH/3839/10/23 Ipsen ⭐ Case of the Week

Ipsen voluntary admission: employee promoted to HCPs in Northern Ireland without verified ABPI representative exam (AUTH/3839/10/23)

Ipsen admitted an employee in a promotional role in Northern Ireland had no verified ABPI representative exam on file. PMCPA ruled breaches…

2023
CASE
AUTH/3803/07/23 GlaxoSmithKline

GSK press release on dostarlimab EAMS found promotional to the public and for an unlicensed indication (AUTH/3803/07/23)

PMCPA ruled GSK’s EAMS press release for dostarlimab was promotional, sent to mainstream media, and promoted an unlicensed indication. Breaches: 5.1, 11.2,…

2023
CASE
AUTH/3806/8/23 AstraZeneca

AstraZeneca breached ABPI Code over missing PI and weak PI signposting on Tagrisso HCP website pop-up (AUTH/3806/8/23)

PMCPA ruled AstraZeneca’s Tagrisso Connect HCP site breached the Code because the first promotional pop-up lacked prescribing information and didn’t clearly signpost…

2023
CASE
AUTH/3809/8/23 Bayer

AUTH/3809/8/23: Complainant v Bayer β€” Advisory board alleged to be pre-licence promotion (No breach on appeal)

Complaint alleged Bayer’s US advisory board was disguised pre-licence promotion of Eylea 8mg. Panel initially found breaches, but Appeal Board overturned them…

2024
CASE
AUTH/3892/4/24 AstraZeneca

AstraZeneca Twitter/X posts about Covid-19 vaccine: one tweet ruled promotional pre-authorisation (AUTH/3892/4/24)

PMCPA reviewed four AstraZeneca UK corporate tweets about its Covid-19 vaccine. Tweets 1–3 were non-promotional corporate updates. Tweet 4 was ruled promotional…

2024
CASE
AUTH/3923/6/24 GlaxoSmithKline ⭐ Case of the Week

AUTH/3923/6/24: Complainant v GSK β€” Trelegy sales aid alleged off-label promotion (No breach)

Anonymous health professional alleged GSK sales aids promoted Trelegy for patients inadequately treated on multiple-inhaler triple therapy (MITT). Panel ruled no breach…

2007
CASE
AUTH/2071/11/07 Takeda

AUTH/2071/11/07: GP v Takeda – Competact/Actos leavepiece and mixed use of relative vs absolute risk

A GP challenged a Takeda promotional leavepiece for pioglitazone that presented benefits as relative risk reduction but harms as absolute risk. The…

2008
CASE
AUTH/2103/3/08 Trinity-Chiesi Pharmaceuticals

AUTH/2103/3/08: Anonymous PCT medicines management team member v Trinity-Chiesi – therapeutic review service (no breach)

Anonymous complaint alleged Trinity-Chiesi sponsored a switch service to Clenil. Panel reviewed the Clinical Support Service documents and process and found no…

2008
CASE
AUTH/2153/8/08 Gamble ⭐ Case of the Week

AUTH/2153/8/08: Actonel leavepiece and use of draft NICE recommendations (Procter & Gamble)

A pharmacist challenged an Actonel leavepiece citing NICE July 2008. The Panel found the title and quotations misleading, including an unbalanced risedronate…

2008
CASE
AUTH/2139/7/08 Roche Products

AUTH/2139/7/08: Consultant rheumatologist v Roche – RCP-sponsored rheumatology webcast (no breach)

A rheumatologist complained that an RCP webcast sponsored by Roche effectively promoted rituximab. The Panel found Roche’s sponsorship was transparent and arm’s…

2008
CASE
AUTH/2126/5/08 Servier Laboratories

AUTH/2126/5/08 Procter & Gamble v Servier Laboratories: misleading and disparaging claims about bisphosphonates and acid suppressants

Servier’s letter, press release and symposium materials implied acid suppressants increased fracture risk and reduced bisphosphonate efficacy. The Panel and Appeal Board…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training